Cholesterol biosynthesis modulation regulates dengue viral replication

Virology

Volumn 389, Issue 1-2, 2009, Pages 8-19

  Rothwell, Christopher ^a   LeBreton, Aude ^a   Young Ng, Chuan ^b   Lim, Joanne Y H ^b   Liu, Wei ^b   Vasudevan, Subhash ^b   Labow, Mark ^a   Gu, Feng ^b   Gaither, L Alex ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Novartis Institutes for Tropical Diseases   (Singapore)

Author keywords

Dengue; Host factors; Mevalonate pyrophosphate decarboxylase; MVD; siRNA; Statins; Viral replication

Indexed keywords

CARBOXYLYASE; CHOLESTEROL; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYMEGLUSIN; MEVALONATE DIPHOSPHODECARBOXYLYASE; MEVINOLIN; RENILLA LUCIFERIN 2 MONOOXYGENASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ZARAGOZIC ACID A;

ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN K 562; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DENGUE VIRUS; GENETIC REGULATION; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REPLICON; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS REPLICATION;

BICYCLO COMPOUNDS, HETEROCYCLIC; CARBOXY-LYASES; CHOLESTEROL; DENGUE VIRUS; FATTY ACIDS, MONOUNSATURATED; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; K562 CELLS; MEVALONIC ACID; POLYISOPRENYL PHOSPHATES; REPLICON; RNA, SMALL INTERFERING; SESQUITERPENES; TRICARBOXYLIC ACIDS; VIRUS REPLICATION;

DENGUE VIRUS; RENILLA; RENILLA LUCIFERASE;

EID: 67349187399     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.03.025     Document Type: Article

References (36)

1. Bengoechea-Alonso M.T., and Ericsson J. SREBP in signal transduction: cholesterol metabolism and beyond. Curr. Opin. Cell. Biol. 2 (2007) 215-222
2. Bennis F., Favre G., Le Gaillard F., and Soula G. Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549. Int. J. Cancer 55 4 (1993) 640-645
3. Bergstrom J.D., Kurtz M.M., Rew D.J., Amend A.M., Karkas J.D., Bostedor R.G., Bansal V.S., Dufresne C., VanMiddlesworth F.L., Hensens O.D., Liesch M., Zink D.L., Wilson K.E., Onishi J., Milligan J.A., Bill G., Kaplan L., Nallin Omstead M., Jenkins R.G., Huang L., Meinz M.S., Quinn L., Burg R.W., Kong Y.L., Mochales S., Mojena M., Martin I., Pelaez F., Diez M.T., and Alberts A.W. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sci. U. S. A. 90 1 (1993) 80-84
4. Borawski J., Lindeman A., Buxton F., Labow M., and Gaither L.A. Optimization procedure for small interfering RNA transfection in a 384-well format. J. Biomol. Screen 12 4 (2007) 546-559
5. Clyde K., Kyle J.L., and Harris E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J. Virol. 80 23 (2006) 11418-11431
6. Cuisset L., Drenth J.P., Simon A., Vincent M.F., van der Velde Visser S., van der Meer J.W., Grateau G., and Delpech M. Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. Eur. J. Hum. Genet. 9 (2001) 260-266
7. del Real G., Jiménez-Baranda S., Mira E., Lacalle R.A., Lucas P., Gómez-Moutón C., Alegret M., Peña J.M., Rodríguez-Zapata M., Alvarez-Mon M., Martínez-A C., and Mañes S. Statins inhibit HIV-1 infection by down-regulating Rho activity. J. Exp. Med. 200 4 (2004) 541-547
8. Goldstein J.L., DeBose-Boyd R.A., and Brown M.S. Protein sensors for membrane sterols. Cell 124 (2006) 35-46
9. Green S., and Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr. Opin. Infect. Dis. 19 5 (2006) 429-436
10. Gualano R.C., Pryor M.J., Cauchi M.R., Wright P.J., and Davidson A.D. Identification of a major determinant of mouse neurovirulence of dengue virus type 2 using stably cloned genomic-length cDNA. J. Gen. Virol. 79 Pt 3 (1998) 437-446
11. Gubler D.J. Dengue and dengue hemorrhagic fever: its history and resurgence as a global public health problem. Dengue and Dengue Hemorrhagic Fever (1997), CAB International, Wallingford, UK 1-22
12. Halstead S.B., Nimmannitya S., and Cohen S.N. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale. J. Biol. Med. 42 (1970) 311-328
13. Fink J., Gu F., Ling L., Tolfvenstam T., Olfat F., Chin K.C., Aw P., George J., Kuznetsov V.A., Schreiber M., Vasudevan S.G., and Hibberd M.L. Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl. Trop. Dis. 1 2 (2007) e86
14. Houten S.M., Schneiders M.S., Wanders R.J., and Waterham H.R. Regulation of isoprenoid/cholesterol biosynthesis in cells from mevalonate kinase-deficient patients. J. Biol. Chem. 278 8 (2003) 5736-5743
15. Ikeda M., Abe K., Yamada M., Dansako H., Naka K., and Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44 1 (2006) 117-125
16. Itakura H., Kita T., Mabuchi H., Matsuzaki M., Matsuzawa Y., Nakaya N., Oikawa S., Saito Y., Sasaki J., Shimamoto K., and The J-LIT Study Group. Relationship between coronary events and serum cholesterol during 10 years of low-dose simvastatin therapy. Circ. J. 72 8 (2008) 1218-1224
17. Jingami H., Brown M.S., Goldstein J.L., Anderson R.G., and Luskey K.L. Partial deletion of membrane-bound domain of 3-hydroxy-3-methylglutaryl coenzyme A reductase eliminates sterol-enhanced degradation and prevents formation of crystalloid endoplasmic reticulum. J. Cell. Biol. 104 6 (1987) 1693-1704
18. Kapadia S.B., and Chisari F.V. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc. Natl. Acad. Sci. U. S. A. 102 7 (2005) 2561-2566
19. Krepkiy D., and Miziorko H.M. Identification of active site residues in mevalonate diphosphate decarboxylase: implications for a family of phosphotransferases. Protein Sci. 13 7 (2004) 1875-1881
20. Ku E.C. Regulation of fatty acid biosynthesis by intermediates of the cholesterol biosynthetic pathway. Biochem. Biophys. Res. Commun. 225 (1996) 173-179
21. Kuhn R.J., Zhang W., Rossmann M.G., Pletnev S.V., Corver J., Lenches E., Jones C.T., Mukhopadhyay S., Chipman P.R., Strauss E.G., Baker T.S., and Strauss J.H. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108 5 (2002) 717-725
22. Ky B., and Rader D.J. The effects of statin therapy on plasma markers of inflammation in patients without vascular disease. Clin. Cardiol. 28 2 (2005) 67-70
23. Lee C.J., Lin H.R., Liao C.L., and Lin Y.L. Cholesterol effectively blocks entry of flavivirus. J. Virol. 82 (2008) 6470-6480
24. Lindenbach B.D., and Rice C.M. Molecular biology of flaviviruses. Adv. Virus. Res. 59 (2003) 23-61
25. Mackenzie J.M., Khromykh A.A., and Parton R.G. Cholesterol manipulation by West Nile virus perturbs the cellular immune response. Cell. Host. Microbe. 2 (2007) 229-239
26. Maksimova E., Yie T.A., and Rom W.N. In vitro mechanisms of lovastatin on lung cancer cell lines as a potential chemopreventive agent. Lung. 186 1 (2008) 45-54
27. Medigeshi G.R., Hirsch A.J., Streblow D.N., Nikolich-Zugich J., and Nelson J.A. West Nile virus entry requires cholesterol-rich membrane microdomains and is independent of alphavbeta3 integrin. J. Virol. 82 (2008) 5212-5219
28. Ng C.Y., Gu F., Phong W.Y., Chen Y.L., Lim S.P., Davidson A., and Vasudevan S.G. Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Antiviral. Res. 76 3 (2007) 222-231
29. Perera R., and Kuhn R.J. Structural proteomics of dengue virus. Curr. Opin. Microbiol. 11 (2008) 369-377
30. Pokidysheva E., Zhang Y., Battisti A.J., Bator-Kelly C.M., Chipman P.R., Xiao C., Gregorio G.G., Hendrickson W.A., Kuhn R.J., and Rossmann M.G. Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell 124 3 (2006) 485-493
31. Pupo-Antúnez M., Rodríguez H., Vázquez S., Vilaseca J.C., Alvarez M., Otero A., and Guzmán G. Monoclonal antibodies raised to the dengue-2 virus (Cuban: A15 strain) which recognize viral structural proteins. Hybridoma 16 4 (1997) 347-353
32. Rigau-Perez J.G., Clark G.G., Gubler D.J., Reiter P., Sanders E.J., and Vorndam A.V. Dengue and dengue haemorrhagic fever. Lancet 352 (1998) 971-977
33. Rothman A.L. Dengue: defining protective versus pathologic immunity. J. Clin. Invest. 113 (2004) 946-951
34. Srikiatkhachorn A., Ajariyakhajorn C., Endy T.P., Kalayanarooj S., Libraty D.H., Green S., Ennis F.A., and Rothman A.L. Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic fever. J. Virol. 81 4 (2007) 1592-1600
35. Vallett S.M., Sanchez H.B., Rosenfeld J.M., and Osborne T.F. A direct role for sterol regulatory element binding protein in activation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene. J. Biol. Chem. 271 21 (1996) 12247-12253
36. Whitehead S.S., Blaney J.E., Durbin A.P., and Murphy B.R. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 5 7 (2007) 518-528